

HHS Public Access

Author manuscript *Am J Ophthalmol.* Author manuscript; available in PMC 2022 August 01.

Published in final edited form as:

Am J Ophthalmol. 2021 August ; 228: 198-204. doi:10.1016/j.ajo.2021.03.050.

Classification criteria for multiple evanescent white dot syndrome

The Standardization of Uveitis Nomenclature (SUN) Working Group*,1,2,3

Abstract

Purpose: To determine classification criteria for multiple evanescent white dot syndrome (MEWDS).

Design: Machine learning of cases with MEWDS and 8 other posterior uveitides.

Methods: Cases of posterior uveitides were collected in an informatics-designed preliminary database, and a final database was constructed of cases achieving supermajority agreement on diagnosis, using formal consensus techniques. Cases were split into a training set and a validation

^{*}Corresponding author: Douglas A. Jabs, MD, MBA, Department of Epidemiology, the Johns Hopkins University Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 20215 USA. Phone: 410-955-1254. djabs@jhmi.edu. CRediT roles: Douglas A. Jabs, MD, MBA: Conceptualization, Methodology, Validation, Investigation, Data curation, Writing--Review and editing, Visualization, Supervision, Project administration, Funding acquisition. Antoine P. Brezin, MD: Investigation, Writing--Review and editing. Andrew D. Dick, MBBS, MD, FRCP, FRCS, FRCOphth: Investigation, Writing--Review and editing. Ralph D. Levinson, MD: Investigation, Writing--Review and editing. Lyndell L. Lim, MD: Investigation, Writing--Review and editing. Peter McCluskey, MD: Investigation, Data curation, Writing--Review and editing. Neal Oden, PhD: Methodology, Software, Validation, Formal analysis, Investigation, Resources, Data curation, Writing--Review and editing. Alan G. Palestine, MD: Investigation, Data curation, Writing--Review and editing. Isrett E. Trusko, PhD, MBA: Methodology, Software, Resources, Data curation, Investigation, Writing--Review and editing. Investigation, Writing--Review and editing. Susan E. Wittenberg, MD: Investigation, Writing--Review and editing. Albert Vitale, MD: Investigation, Writing--Review and editing. Susan E. Wittenberg, MD: Investigation, Writing-Review and editing.

 ¹Writing committee: Douglas A. Jabs, MD, MBA^{2,3}; Antoine P. Brezin, MD⁴; Andrew D. Dick, MBBS, MD, FRCP, FRCS, FRCOphth^{5–7}; Ralph D. Levinson, MD⁸; Lyndell L. Lim, MD⁹; Peter McCluskey, MD¹⁰; Neal Oden, PhD¹¹; Alan G. Palestine, MD¹²; Jennifer E. Thorne, MD, PhD^{2,3}; Brett E. Trusko, PhD, MBA¹³; Albert Vitale, MD¹⁴; Susan E. Wittenberg, MD¹⁵
²Affiliations: ¹Members of the SUN Working Group are listed online at ajo.com. From ²the Department of Epidemiology, the Johns Hopkins University Bloomberg School of Public Health, and ³the Wilmer Eye Institute, the Department of Ophthalmology, the Johns Hopkins University School of Medicine, Baltimore, MD, USA; ⁴Department of Ophthalmology, University of Paris V – Hôpital Cochin, Paris, France; ⁵the Academic Unit of Ophthalmology, Bristol Medical School, University of Bristol, Bristol, UK; ⁶the National Institute for Health Research Biomedical research Centre at Moorfields Eye Hospital, London, UK; ⁷University College London Institute of Ophthalmology, London UK; ⁸the UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; ⁹Center for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia; ¹¹the Emmes Company, LLC, Rockville, MD, USA; ¹²the Department of Ophthalmology, University of Colorado School of Medicine, Aurora, Co, USA; ¹³the Department of Medicine, Salt Lake City, UT, USA; ¹⁵Houston Eye Associates, Houston, TX, USA.
³Conflict of Interest: Douglas A. Jabs: none; Antoine Brezin: none; Andrew Dick: none; Ralph Levinson: none; Lyndell L. Lim:

³**Conflict of Interest:** Douglas A. Jabs: none; Antoine Brezin: none; Andrew Dick: none; Ralph Levinson: none; Lyndell L. Lim: none; Peter McCluskey: none; Neal Oden: none; Alan G. Palestine: none; Jennifer E. Thorne: Dr. Thorne engaged in a portion of this research as a consultant and was compensated for the consulting service; Brett E. Trusko: none; Albert Vitale: none; Susan E. Wittenberg: none.

Conflict of Interest: Douglas A. Jabs: none; Antoine Brezin: none; Andrew Dick: none; Ralph Levinson: none; Lyndell L. Lim: none; Peter McCluskey: none; Neal Oden: none; Alan G. Palestine: none; Jennifer E. Thorne: Dr. Thorne engaged in a portion of this research as a consultant and was compensated for the consulting service; Brett E. Trusko: none; Albert Vitale: none; Susan E. Wittenberg: none.

Publisher's Disclaimer: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

set. Machine learning using multinomial logistic regression was used on the training set to determine a parsimonious set of criteria that minimized the misclassification rate among the infectious posterior/panuveitides. The resulting criteria were evaluated on the validation set.

Results: One thousand sixty-eight cases of posterior uveitides, including 51 cases of MEWDS, were evaluated by machine learning. Key criteria for MEWDS included: 1) multifocal gray white chorioretinal spots with foveal granularity; 2) characteristic imaging on fluorescein angiography ("wreath-like" hyperfluorescent lesions) and/or optical coherence tomography (hyper-reflective lesions extending from retinal pigment epithelium through ellipsoid zone into the retinal outer nuclear layer); and 3) absent to mild anterior chamber and vitreous inflammation. Overall accuracy for posterior uveitides was 93.9% in the training set and 98.0% (95% confidence interval 94.3, 99.3) in the validation set. The misclassification rates for MEWDS were 7% in the training set and 0% in the validation set.

Conclusions: The criteria for MEWDS had a low misclassification rate and appeared to perform sufficiently well for use in clinical and translational research.

PRECIS

Using a formalized approach to developing classification criteria, including informatics-based case collection, consensus-technique-based case selection, and machine learning, classification criteria for multiple evanescent white dot syndrome were developed. Key criteria included multifocal chorioretinal gray spots with foveal granularity, absent to mild anterior chamber and vitreous inflammation, and either a characteristic fluorescein angiogram ("wreath-like" hyperfluorescence) and/or optical coherence tomogram (lesions extending from retinal pigment epithelium into retina). The resulting classification criteria had a low misclassification rate.

In 1984 Jampol et al¹ described a new posterior uveitis, which they named multiple evanescent white dot syndrome (MEWDS). The disease occurred in young people (mean age 28 years), predominantly women (90%), and was characterized by unilateral, 100 to 200 µm gray-white dots at the level of the retinal pigment epithelium or outer retina and a foveal granularity. Other common features included posterior vitreous cells, disc swelling with fluorescein staining, and less often vascular sheathing. The white spots had a characteristic wreath-like appearance on fluorescein angiography. The disease spontaneously remitted over ~2 months with recovery of normal or near normal (20/30 or better) acuity in all cases. No systemic disease was evident, and no treatment appeared warranted.

Subsequent case series have confirmed the clinical features of the disease.^{2–6} The disease presents in young adults; approximately 80% of cases are in women; there is no evident racial or ethnic predilection. Rare cases of bilateral disease and recurrent disease have been reported,⁷ but the large majority of cases are unilateral with a self-limited disease.^{4,6}

Multiple evanescent white dot syndrome is a rare disease. The incidence has been estimated at 0.22 per 100,000 population per year, an incidence on the same order of magnitude as acute posterior multifocal placoid pigment epitheliopathy (APMPPE).⁸ The etiology is unknown. A post-viral autoimmune or auto-inflammatory pathogenesis has been postulated, as case series suggest that ~50% of patients with MEWDS will have an antecedent flu-like

illness.^{1,4} However, these case series suffer from recall bias and lack of a control group, making inferences about pathogenesis speculative.

Multimodal imaging is helpful in evaluating the disease.^{5,6} Fluorescein angiography demonstrates early hyperfluorescence of the multifocal white spots and a "wreath-like" pattern in ~80% of cases.^{4,6} Indocyanine green (ICG) angiography demonstrates early to mid-phase hypofluorescence of the white dots and a peripapillary zonal hypofluorescence, the latter of which correlates with the enlarged blind spot often present in patients with MEWDS.^{4,6} Optical coherence tomography (OCT) imaging demonstrates disruption of the ellipsoid zone and either dome-shaped hyperreflectivity over the retinal pigment epithelium and/or vertical linear hyperreflectivityl involving the ellipsoid zone and outer nuclear layer, the latter being seen in ~80% of cases evaluated with OCT.^{5,6,9} Although there is debate about the exact pathogenesis and the extent of the involvement of the choroid,¹⁰ these outer retinal findings may help to distinguish MEWDS from other multifocal choroidopathies. Fundus autofluorescence, evaluated in a limited number of cases, demonstrates hyper-autofluorescence of the lesions.^{11,12}

No treatment typically is given as eyes spontaneously recover in ~10 weeks with 95% of eyes achieving 20/25 or better.^{1,4,6}

The Standardization of Uveitis Nomenclature (SUN) Working Group is an international collaboration, which has developing classification criteria for 25 of the most common uveitides using a formal approach to development and classification. Among the diseases studied was MEWDS.^{13–18}

Methods

The SUN Developing Classification Criteria for the Uveitides project proceeded in four phases as previously described: 1) informatics, 2) case collection, 3) case selection, and 4) machine learning.^{15–18}

Informatics.

As previously described, the consensus-based informatics phase permitted the development of a standardized vocabulary and the development of a standardized, menu-driven hierarchical case collection instrument.¹⁵

Case collection and case selection.

De-identified information was entered into the SUN preliminary database by the 76 contributing investigators for each disease as previously described.^{17,18} Cases in the preliminary database were reviewed by committees of 9 investigators for selection into the final database, using formal consensus techniques described in the accompanying article.^{17,18} Because the goal was to develop classification criteria,¹⁹ only cases with a supermajority agreement (>75%) that the case was the disease in question were retained in the final database (i.e. were "selected").^{17,18}

Machine learning.

The final database then was randomly separated into a training set (~85% of the cases) and a validation set (~15% of the cases) for each disease as described in the accompanying article.¹⁸ Machine learning was used on the training set to determine criteria that minimized misclassification. The criteria then were tested on the validation set; for both the training set and the validation set, the misclassification rate was calculated for each disease. The misclassification rate was the proportion of cases classified incorrectly by the machine learning algorithm when compared to the consensus diagnosis. For MEWDS, the diseases against which it was evaluated included: APMPPE, birdshot chorioretinitis (BSCR), multifocal choroiditis with panuveitis (MFCPU), punctate inner choroiditis (PIC), serpiginous choroiditis, sarcoidosis-associated posterior uveitis, syphilitic posterior uveitis, and tubercular uveitis.

The study adhered to the principles of the Declaration of Helsinki. Institutional Review Boards (IRBs) at each participating center reviewed and approved the study; the study typically was considered either minimal risk or exempt by the individual IRBs.

Results

Ninety-five cases of MEWDS were collected, and 51 (54%) achieved supermajority agreement on the diagnosis during the "selection" phase and were used in the machine learning phase These cases of MEWDS were compared to cases of posterior uveitides, including 82 cases of APMPPE, 207 cases of BSCR, 122 cases of serpiginous choroiditis, 138 cases of MFCPU, 144 cases of PIC, 12 cases of sarcoid posterior uveitis, 35 cases of syphilitic posterior uveitis, and 277 cases of tubercular posterior/panuveitis (including 96 cases of serpiginous-like tubercular choroiditis). The details of the machine learning results for these diseases are outlined in the accompanying article.¹⁹ The characteristics of cases with MEWDS are listed in Table 1, and the classification criteria developed after machine learning are listed in Table 2. Key features of the criteria include multifocal white dots (Figure 1), the characteristic "wreath-like" hyperfluorescent lesions on fluorescein angiogram (Figure 2), and the hyperreflective lesions extending from the retinal pigment epithelium inward on OCT (Figure 3). The overall accuracies for posterior uveitides were 93.9% in the training set and 98.0% (95% confidence interval 94.3, 99.3) in the validation set. The misclassification rate for MEWDS in the training set was 7%, and in the validation set it was 0%.

Discussion

The classification criteria developed by the SUN Working Group for MEWDS have an acceptable misclassification rate, indicating good discriminatory performance against other non-infectious posterior and pan-uveitides. Because the goal of the SUN criteria is classification at presentation, and because MEWDS spontaneously resolves, these criteria are most appropriate for the early, active, stage of the disease.²⁰

Unlike other diseases in this class, the primary lesion appears to be at the level of the retinal pigment epithelium and/or outer retina. The OCT appearance therefore is helpful in

distinguishing MEWDS from other posterior uveitides. Placoid syphilitic posterior uveitis has a "ratty" appearance to the retinal pigment epithelium,²¹ but typically is a unifocal or paucifocal disease. Nevertheless, its exclusion appears warranted. Similarly, the fluorescein angiographic appearance, when present, distinguishes MEWDS from the other diseases in this class, and is useful in the diagnosis. Features which do not discriminate between diseases, such as hypofluorescent spots on ICG and choroidal thickening would not be selected.^{22,23} Although peripapillary zonal hypofluorescence on ICG is highly suggestive of MEWDS, it was not reported often enough to be selected as a criterion. Further study evaluating this finding in a series of patients diagnosed using standardized criteria could lead to a revision of the criteria.

The presence of any of the exclusions in Table 2 suggests an alternate diagnosis, and the diagnosis of MEWDS should not be made in their presence. In prospective studies many of these tests will be performed routinely, and the alternative diagnoses excluded. However, in retrospective studies based on clinical care, not all of these tests may have been performed. In these studies the presence of an exclusionary criterion excludes MEWDS, but the absence of such testing does <u>not</u> always exclude the diagnosis of MEWDS if the criteria for the diagnosis are met. Cases mimicking the clinical and imaging features of MEWDS have been reported, including cases of syphilis and sarcoidosis; most of the diseases mimicking MEWDS were bilateral at presentation (bilateral simultaneous onset).²⁴ Nearly all cases of MEWDS are unilateral at onset. Going forward, it would seem appropriate to evaluate patients for more common masquerading diseases, using appropriate serology for syphilis and chest imaging for sarcoidosis.^{25,26}

Classification criteria are employed to diagnose individual diseases for research purposes.¹⁹ Classification criteria differ from clinical diagnostic criteria, in that although both seek to minimize misclassification, when a trade-off is needed, diagnostic criteria typically emphasize sensitivity, whereas classification criteria emphasize specificity,¹⁹ in order to define a homogeneous group of patients for inclusion in research studies and limit the inclusion of patients without the disease in question that might confound the data. The machine learning process employed did not explicitly use sensitivity and specificity; instead it minimized the misclassification rate. Because we were developing classification criteria and because the typical agreement between two uveitis experts on diagnosis is moderate at best,¹⁷ the selection of cases for the final database ("case selection") included only cases which achieved supermajority agreement on the diagnosis. As such, some cases which clinicians would diagnose with MEWDS may not be so classified by classification criteria.

In conclusion, the criteria for MEWDS outlined in Table 2 appear to perform sufficiently well for use as classification criteria in clinical research.¹⁸

Acknowledgments

Grant support: Supported by grant R01 EY026593 from the National Eye Institute, the National Institutes of Health, Bethesda, MD, USA; the David Brown Fund, New York, NY, USA; the Jillian M. And Lawrence A. Neubauer Foundation, New York, NY, USA; and the New York Eye and Ear Foundation, New York, NY, USA.

- 1. Jampol LM, Sieving PA, Pugh D, Fishman GA, Gilbert H. Multiple evanescent white dot syndrome. I. Clinical findings. Arch Ophthalmol 1984;102:671–4. [PubMed: 6721749]
- Gross NE, Yannuzzi LA, Freund B, Spaide RF. Multiple evanescent white dot syndrome. Arch Ophthalmol 2006;124:493–500. [PubMed: 16606874]
- 3. Hanagi M, Fujimoto M, Yoshimura N. Features and function of multiple evanescent white dot syndrome. Arch Ophthalmol 2009;127:1307–13. [PubMed: 19822847]
- 4. dell'Omo R, Pavesio CE. Multiple evanescent white dot syndrome (MEWDS). Intern Ophthalmol Clin 2012;4:221–8.
- Boretsky A, Mizra S, Khan F, Motamedi M, van Kuijk FJGM. High-resolution multimodal imaging of multiple evanescent white dot syndrome. Ophthalmic Surg Lasers Imaging Retina 2013;44:296– 300. [PubMed: 23676237]
- Marsiglia M, Gallego-Pinazo R, Cunha De Souza E, et al. Expanded clinical spectrum of multiple evanescent white doe syndrome with multimodal imaging. Retina 2016;36:64–74. [PubMed: 26166804]
- Aaberg TM, Campo RV, Joffe L. Recurrences and bilaterality in multiple evanescent white dot syndrome. Am J Ophthalmol 1985;100:29–37. [PubMed: 4014377]
- Abu-Yaghi NE, Hartono SP, Hodge DO, Pulido JS, Bakri SJ. White dot syndromes: a 20-year study of incidence, lcinical features, and outcomes. Ocular Immunol Inflamm 2011;19:426–30.
- 9. Nguyen MHT, Witkin AJ, Reichel E, et al. Microstructural abnormalities in MEWDS demonstrated by ultrahigh resolution optical coherence tomography. Retina 2007;27:414–8. [PubMed: 17420691]
- Lages V, Mantovani A, Papadia M, Herbort CP. MEWDS is a true primary choriocapillaritis and basic mechanisms do not seem to differ from other choriocapillaritis entities. J Current Opphtalmol 2018;30:281–6.
- 11. Furino C, Boscia F, Cardascia N, Alessio G, Sborgia C. Fundus autofluorescence and multiple evanescent white dot syndrome. Retina 2009;29:60–3. [PubMed: 18936716]
- Joseph A, Rahimy E, Freund KB, Sorenson JA, Sarraf D. Fundus autofluorescence and photoreceptor bleaching in multiple evanescent white dot syndrome. Ophthalmic Surg Lasers Imaging Retina 2013;44:588–92. [PubMed: 24221465]
- Jabs DA, Rosenbaum JT, Nussenblatt RB, the Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Report of the first international workshop. Am J Ophthalmol 2005;140:509–16. [PubMed: 16196117]
- Jabs DA, Busingye J. Approach to the diagnosis of the uveitides. Am J Ophthalmol 2013;156:228– 36. [PubMed: 23668682]
- Trusko B, Thorne J, Jabs D, et al. Standardization of Uveitis Nomenclature Working Group. The SUN Project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med 2013;52:259–65. [PubMed: 23392263]
- 16. Okada AA, Jabs DA. The SUN Project. The future is here. Arch Ophthalmol 2013;131:787-9.
- 17. Jabs DA, Dick A, Doucette JT, Gupta A, Lightman S, McCluskey P, Okada AA, Palestine AG, Rosenbaum JT, Saleem SM, Thorne J, Trusko, B for the Standardization of Uveitis Nomenclature Working Group. Interobserver agreement among uveitis experts on uveitic diagnoses: the Standard of Uveitis Nomenclature Experience. Am J Ophthalmol 2018; 186:19–24. [PubMed: 29122577]
- 18. The Standardization of Uveitis Nomenclature (SUN) Working Group. Development of classification criteria for the uveitides. Am J Ophthalmol 2020;volume:pp.
- 19. Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria. Arthritis Care Res 2015;67:891–7.
- 20. Cahuzac A, Wolff B, Mathis T, et al. Multimodal imaging in 'hyper-early' stage MEWDS. Brit J Ophthalmol 2017;101:1381–5. [PubMed: 28202480]
- Pichi F, Ciardella AP, Cunningham ET, et al. Spectral domain optical coherence tomography findings in patients with acute syphilitic posterior placoid chorioretinopathy. Retina 2014;34:373– 84. [PubMed: 23860561]

- 22. Fiore T, Iaccheri B, Cerquaglia A, et al. Outer retinal choroidal evaluation in multiple evenaescent white dot syndrome (MEWDS); an enhanced depth imaging optical coherence tomography study. Ocualr Immunol Inflamm 2018:26:428–34.
- 23. Pellegrini M, Veronese C, Bernabei F, et al. Choroidal vascular changes in multiple evanescent white dot syndrome. Ocular Immunol Inflamm 2019; ePub ahead of print.
- 24. Russell JF, Pichi F, Scott NL, et al. Masqueraders of multiple evanescent white dot syndrome (MEWDS). Int Ophthalmol 2020;40:627–38. [PubMed: 31792848]
- 25. Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for syphilitic uveitis. Am J Ophthalmol 2020;vol;pp.
- 26. Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for sarcoidosis-associated uveitis. Am J Ophthalmol 2020;vol:pp.



Figure 1.

Fundus photograph of a case of multiple evanescent white dot syndrome, demonstrating the characteristic white chorioretinal lesions.



Figure 2.

Fluorescein angiogram of a case of multiple evanescent white dot syndrome, demonstrating the "wreath-like" nature of the chorioretinal lesions.



Figure 3.

Optical coherence tomogram of a case of multiple evanescent white dot syndrome, demonstrating the characteristic lesions in the ellipsoid zone and outer nuclear layer.

Table 1.

Characteristics of Cases with Multiple Evanescent White Dot Syndrome

Characteristic	Result
Number cases	51
Demographics	
Age, median, years (25 th 75 th percentile)	27 (22, 34)
Gender (%)	
Men	24
Women	76
Race/ethnicity (%)	
White, non-Hispanic	61
Black, non-Hispanic	0
Hispanic	4
Asian, Pacific Islander	6
Other	10
Missing	19
Uveitis History	
Uveitis course (%)	
Acute, monophasic	87
Acute, recurrent	6
Chronic	2
Indeterminate	5
Laterality (%)	
Unilateral	96
Unilateral, alternating	2
Bilateral	2
Ophthalmic examination	
Keratic precipitates (%)	
None	100
Anterior chamber cells (%)	
Grade 0	90
1⁄2+	6
1+	4
2+	0
3+	0
4+	0
Anterior chamber flare (%)	
Grade 0	100
Iris (%)	
Normal	100

CharacteristicResultIntraccular pressure (OP), involved eyes14 (12, 16)Monortion patients with IOP>24 nm Hg either eye (%)14 (12, 16)Viroux cells (%)15Grade O591/414211/414211/414211/414211/4163/401/4163/401/416 </th <th></th> <th></th>		
Intracular pressure (IOP), involved eyesIMedian, nm Hg (2s th , 7s th percentile)I (4 (2.16)Proprior patients with IOP-24 nm Hg either eye (%)0Vircou cells (%)59Grade 059½-141421414263-04-04-0Vircous haze (%)0Grade 096½-4140140140140140140140140140140140140140140140140150160170180190190100100110120140150160160170180190190100100100110120130140140150160160170180<	Characteristic	Result
Median, mm Hg (25 th , 75 th percentile)I4 (12, 16)Proportion patients with IOP>24 mm Hg either eye (%)0Vitreous cells (%)59Grade 059½+221+142-163+0440Vitreous haze (%)65959½+6609½+0140140140140140140140140140140140140140140140150140140140150160170180190100140140140150160170180190100100110120130140140150160170180190190190190190 <td< td=""><td>Intraocular pressure (IOP), involved eyes</td><td></td></td<>	Intraocular pressure (IOP), involved eyes	
Proportion patients with IOP>24 mm Hg either eye (%)0Vitreous cells (%)59½+221+142+663+04+0Vitreous haze (%)7Grade 096½+414914-914-1014-914-1014-1014-1014-1014-1014-1014-1014-102+103+04+0014-0014-0014-1015-1616-1616-1617-1618-1019-1019-1010-1010-1010-1011-1012-1013-1014-1015-1616-1616-1617-1618-1619-1619-1619-1619-1619-1619-1619-1619-1619-1619-1619-1619-1619-1619-1619-16<	Median, mm Hg (25 th , 75 th percentile)	14 (12, 16)
Vireous cells (%)Image: state	Proportion patients with IOP>24 mm Hg either eye (%)	0
Grade 059½+221+142+63+04+0Grade 096½+41+0½+41+02+03+03+03+04+0102+03+04+0Choirertinal lesion characteristics0Unifocal (1 lesion)9Pauifocal (2-4)16Multifocal (5)75Missing9Lesion shape & character (%)0Panchoid or serpentine0Oval or round88Placoid0Punched-out atrophic0Punctae0Nissing01414Missing01414151415141614161416141714181419141914111411141214131414141514151415141514151415141514151415141614161714	Vitreous cells (%)	
½+ 22 1+ 14 2+ 6 3+ 0 4+ 0 Vireous haze (%) 0 Grade 0 96 ½+ 4 1+ 0 ½+ 4 1+ 0 2+ 0 3+ 0 4+ 0 Chrioretinal lesion characteristics 0 Lesion number (%) 0 Unifocal (1 lesion) 0 Paucifocal (2-4) 16 Multifocal (5) 75 Missing 9 Lesion supe & character (%) 75 Aneboid or sepentine 0 Oval or round 85 Placoid 0 Punctae 0 Punctae 14	Grade 0	59
1+142+63+04+0Vireous haze (%)965961+01+02+03+04+0Chroirertinal lesion characteristics0Lesion number (%)0Quiriccal (1 lesion)0Paucificcal (2-4)16Multificcal (5)75Missing0Quiri or serpentine0Oval or serpentine0Pancid85Placoid0Puncted-out strophic0Puncted-out strophic0Puncted14Missing0Puncted14Missing0Puncted14Missing0Puncted14Missing0Puncted14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14Missing14	1/2+	22
2+ 6 3+ 0 4+ 0 Vitrous hare (%) 96 ½+ 4 1+ 0 2+ 0 3+ 0 2+ 0 3+ 0 4+ 0 Chorioretinal lesion characteristics 0 Lesion number (%) 1 Multifocal (1 lesion) 0 Paucifocal (2-4) 16 Multifocal (5) 75 Missing 9 Lesion sape & character (%) 0 Ameboid or serpentine 0 Oval or round 85 Placoid 0 Punctate 0 Punctater (%) 14 Missing 0 Placoid 0 Punctate 0 Punctater (%) 0 Punctate 0 Punctate 0 Punctate 0 Punctate 0 Punctate 0 Punctate 0	1+	14
3+ 0 4+ 0 Vireous haze (%) 96 ½+ 4 1+ 0 2+ 0 3+ 0 4+ 0 Chorioretinal lesion characteristics 0 Lesion number (%) 0 Quiccal (1-lsion) 0 Paucifocal (2-4) 16 Multifocal (5) 75 Missing 0 Lesion sape & character (%) 0 Ameboid or serpentine 0 Oval or round 85 Placoid 0 Punctate rouphic 0 <	2+	6
4+ 0 Vireous haze (%) 96 Grade 0 96 ½+ 4 1+ 0 2+ 0 3+ 0 4+ 0 Chrioretinal lesion characteristics 0 Lesion number (%) 1 Unifocal (1 lesion) 0 Paucifocal (2-4) 16 Multifocal (5) 75 Missing 9 Lesion shape & character (%) 75 Mussing 0 Placoid 85 Placoid 0 Punctate 0 Nussing 1	3+	0
Vitrous haze (%) Image: mathematical states of the states of	4+	0
Grade 0 96 ½+ 4 1+ 0 2+ 0 3+ 0 4+ 0 Chorioretinal lesion characteristics 0 Lesion number (%) 1 Unifocal (1 lesion) 0 Paucifocal (2-4) 16 Multifocal (5) 75 Missing 9 Lesion shape & character (%) 9 Placoid or serpentine 0 Oval or round 85 Placoid 9 Punched-out atrophic 0 Punched-out atrophic 0 Nissing 14	Vitreous haze (%)	
½+ 4 1+ 0 2+ 0 3+ 0 4+ 0 Chorioretinal lesion characteristics 0 Lesion number (%) 1 Unifocal (1 lesion) 0 Paceifocal (2-4) 16 Multifocal (5) 75 Missing 9 Lesion shape & character (%) 0 Oval or round 85 Placoid 0 Punched-out atrophic 0 Punched-out atrophic 0 Nussing 14	Grade 0	96
1+ 0 2+ 0 3+ 0 4+ 0 Chorioretinal lesion characteristics 0 Lesion number (%) 1 Unifocal (1 lesion) 0 Paucifocal (2-4) 16 Multifocal (5) 75 Missing 9 Lesion shape & character (%) 0 Oval or round 85 Placoid 0 Punched-out atrophic 0 Punctae 14 Missing 14	1/2+	4
2+ 0 3+ 0 4+ 0 Chorioretinal lesion characteristics 0 Lesion number (%) 0 Unifocal (1 lesion) 0 Paucifocal (2-4) 16 Multifocal (5) 75 Missing 9 Lesion shape & character (%) 0 Ameboid or serpentine 0 Oval or round 85 Placoid 0 Punched-out atrophic 0 Punctate 14 Missing 14	1+	0
3+04+0Chorioretinal lesion characteristics0Lesion number (%)0Unifocal (1 lesion)0Paucifocal (2-4)16Multifocal (5)75Missing9Lesion shape & character (%)0Ameboid or serpentine0Oval or round85Placoid0Punched-out atrophic0Punctate14Missing1	2+	0
4+0Chorioretinal lesion characteristicsLesion number (%)Unifocal (1 lesion)0Paucifocal (2-4)16Multifocal (5)75Missing9Lesion shape & character (%)Ameboid or serpentine0Oval or round85Placoid0Punched-out atrophic0Punctate14Missing14	3+	0
Chorioretinal lesion characteristics I Lesion number (%) 0 Unifocal (1 lesion) 0 Paucifocal (2-4) 16 Multifocal (5) 75 Missing 9 Lesion shape & character (%) 0 Ameboid or serpentine 0 Oval or round 85 Placoid 0 Punched-out atrophic 0 Punctate 14 Missing 1	4+	0
Lesion number (%)IUnifocal (1 lesion)0Paucifocal (2-4)16Multifocal (5)75Missing9Lesion shape & character (%)0Ameboid or serpentine0Oval or round85Placoid0Punched-out atrophic0Punctate14Missing1	Chorioretinal lesion characteristics	
Unifocal (1 lesion)0Paucifocal (2-4)16Multifocal (5)75Missing9Lesion shape & character (%)0Ameboid or serpentine0Oval or round85Placoid0Punched-out atrophic0Punctate14Missing1	Lesion number (%)	
Paucifocal (2-4)16Multifocal (5)75Missing9Lesion shape & character (%)0Ameboid or serpentine0Oval or round85Placoid0Punched-out atrophic0Punctate14Missing1	Unifocal (1 lesion)	0
Multifocal (5)75Missing9Lesion shape & character (%)0Ameboid or serpentine0Oval or round85Placoid0Punched-out atrophic0Punctate14Missing1	Paucifocal (2–4)	16
Missing9Lesion shape & character (%)0Ameboid or serpentine0Oval or round85Placoid0Punched-out atrophic0Punctate14Missing1	Multifocal (5)	75
Lesion shape & character (%) 0 Ameboid or serpentine 0 Oval or round 85 Placoid 0 Punched-out atrophic 0 Punctate 14 Missing 1	Missing	9
Ameboid or serpentine0Oval or round85Placoid0Punched-out atrophic0Punctate14Missing1	Lesion shape & character (%)	
Oval or round85Placoid0Punched-out atrophic0Punctate14Missing1	Ameboid or serpentine	0
Placoid 0 Punched-out atrophic 0 Punctate 14 Missing 1	Oval or round	85
Punched-out atrophic 0 Punctate 14 Missing 1	Placoid	0
Punctate 14 Missing 1	Punched-out atrophic	0
Missing 1	Punctate	14
Levin Levin (00)	Missing	1
Lesion location (%)	Lesion location (%)	
Posterior pole involved 47	Posterior pole involved	47
Mid-periphery and periphery only 53	Mid-periphery and periphery only	53
Typical lesion size (%)	Typical lesion size (%)	
<125 µm 14	<125 µm	14
125–250 μm 55	125–250 μm	55
250–500 μm 29	250–500 μm	29
>500 µm 2	>500 µm	2
Other features (%)	Other features (%)	

Characteristic	Result
Retinal vascular sheathing	8
Retinal vascular leakage	14
Choroidal neovascularization	0
Imaging results	
"Wreath-like" staining of spots on fluorescein angiogram*	65
Hyperreflective lesions extending from retinal pigment epithelium into or through ellipsoid zone on optical coherence tomography †	88

* Based on 40 cases with fluorescein angiography.

 ${^{\not\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!}}Based on 26 cases with optical coherence tomography results.$

Table 2.

Criteria

1. Multifocal chorioretinal gray-white spots with foveal granularity

AND

2. Characteristic fluorescein angiogram or optical coherence tomogram (OCT)

a. "Wreath-like" hyperfluorescent lesions on fluorescein angiogram OR

b. Hyperreflective lesions on OCT extending from the retinal pigment epithelium, into and/or through the ellipsoid zone into the outer nuclear layer of the retina

AND

3. Absent to mild anterior chamber and vitreous inflammation

Exclusions

1. Positive serologic test for syphilis using a treponemal test

2. Evidence of sarcoidosis (either bilateral hilar adenopathy on chest imaging or tissue biopsy demonstrating non-caseating granulomata)

3. Bilateral simultaneous disease onset